Taysha Gene Therapies (NASDAQ:TSHA) Given Buy Rating at Chardan Capital

Chardan Capital reiterated their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a $7.00 price target on the stock.

Several other brokerages have also recently commented on TSHA. Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday. Needham & Company LLC restated a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday. Canaccord Genuity Group cut their target price on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, August 14th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Stock Down 9.7 %

Shares of TSHA traded down $0.22 during mid-day trading on Thursday, reaching $2.05. The company’s stock had a trading volume of 2,805,118 shares, compared to its average volume of 2,596,851. The company’s 50 day moving average is $1.98 and its 200 day moving average is $2.39. The stock has a market cap of $420.13 million, a PE ratio of 3.32 and a beta of 0.44. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.22 and a quick ratio of 5.22. Taysha Gene Therapies has a 12-month low of $1.19 and a 12-month high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01. The company had revenue of $1.11 million during the quarter, compared to analyst estimates of $3.62 million. Taysha Gene Therapies had a negative return on equity of 109.58% and a negative net margin of 229.67%. During the same period in the prior year, the company earned ($0.38) earnings per share. Equities analysts anticipate that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Taysha Gene Therapies

Institutional investors and hedge funds have recently bought and sold shares of the company. Avoro Capital Advisors LLC boosted its position in Taysha Gene Therapies by 328.2% during the 1st quarter. Avoro Capital Advisors LLC now owns 18,650,000 shares of the company’s stock valued at $53,526,000 after acquiring an additional 14,294,445 shares in the last quarter. Artal Group S.A. increased its stake in Taysha Gene Therapies by 0.7% in the 1st quarter. Artal Group S.A. now owns 3,687,548 shares of the company’s stock worth $10,583,000 after buying an additional 24,444 shares in the last quarter. StemPoint Capital LP purchased a new position in shares of Taysha Gene Therapies during the first quarter valued at about $3,122,000. Quantum Private Wealth LLC grew its position in shares of Taysha Gene Therapies by 5.1% during the third quarter. Quantum Private Wealth LLC now owns 767,616 shares of the company’s stock valued at $1,543,000 after purchasing an additional 37,096 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Taysha Gene Therapies by 7.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 462,867 shares of the company’s stock valued at $930,000 after acquiring an additional 33,123 shares during the last quarter. 77.70% of the stock is owned by institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.